VXRT - Should You Buy Vaxart Stock in March?
Vaxart (NASDAQ: VXRT) started last month on a sour note. The phase 1 trial data for its investigational coronavirus vaccine was disappointing, and its stock sank by 58% in a single trading session. The reason: Vaxart's candidate lacked one quality considered key for a successful vaccine.
But there was a bright spot within the trial data. And the company is relying on that bright spot as it advances the investigational vaccine into phase 2 trials during the second quarter. Now the question for investors is whether they should believe in Vaxart once again -- and buy shares of the clinical-stage biotech.
Image source: Getty Images.
For further details see:
Should You Buy Vaxart Stock in March?